Skip to main content

Specialty Pharmacy

  • FDA gives tentative approval to Cipla combo pill for HIV

    SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a new drug for HIV made by an Indian company.

    FDA records show that the agency gave tentative approval tablets and oral suspension that combine lamivudine, nevirapine and zidovudine in the 30-mg/50-mg/60-mg strength.

  • FDA approves first drug for eye condition

    SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.

    The agency announced the approval of Jetrea (ocriplasmin), made by Iselin, N.J.-based ThromboGenics. The drug is used to treat symptomatic vitreomacular adhesion.

  • Bristol-Myers Squibb skin cancer drug wins Prix Galien USA Prize

    PRINCETON, N.J. — A cancer drug made by Bristol-Myers Squibb has received an award from Galien Foundation, the drug maker said Wednesday.

    The company said Yervoy (ipilimumab) received the 2012 Prix Galien USA Prize in the Best Biotechnology Product category. Yervoy — used to treat melanoma that has spread to other parts of the body, known as metastasis — is the first new drug for melanoma that is metastatic or can't be removed through surgery in more than a decade.

  • FDA approves new use for Genentech arthritis drug

    SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

    The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.

  • BD introduces disposable injection pen

    FRANKLIN LAKES, N.J. — Medical supply company BD has introduced a disposable injection pen that it said was designed for drugs requiring frequent, low-volume injections or variable dosing.

    The company's BD Medical division announced the introduction of the Vystra, which it will showcase at the 2012 Parenteral Drug Association meeting in Las Vegas.

    The company said the pen is designed for ease of use, comfort and reliability, including design features like multi-dosing, simple dose dialing and correction with audible clicks and large and clear dose markings.

  • FDA approves Celgene lung-cancer drug

    SUMMIT, N.J. — The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.

    Celgene announced the approval of Abraxane (paclitaxel) protein-bound particles for injectable suspension, for the first-line treatment of non-small cell lung cancer that has advanced locally or spread to other parts of the body, in combination with carboplatin, for patients who are not candidates for curative surgery or radiation therapy.

  • Merck KGaA to donate $1.3 million per year to academic MS research

    ROCKLAND, Mass. — A German drug maker is pledging millions of dollars for multiple sclerosis research, the company's U.S. subsidiary said Thursday.

  • Medicine-On-Time launches site to promote medication adherence system

    HUNT VALLEY, Md. — A company that manufactures simplified packaging designed to increase medication adherence has launched a new website to promote the product.

    Medicine-On-Time announced the launch of a new website that connects patients to pharmacies that offer the packaging. The launch includes 250 pharmacies around the country, a number that the company expects to grow. The packaging system is geared toward patients taking multiple drugs and uses personalized pill cups labeled with the day, date and time to take them.

X
This ad will auto-close in 10 seconds